ReviewFrontiers in medicine2021
Risk Factors for Mucosal Involvement in Bullous Pemphigoid and the Possible Mechanism: A Review.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Mucosal Involvement in Bullous Pemphigoid: Severity Indicator and Associated Clinical Features from a Retrospective Cohort Study.Journal of inflammation research · 2026Article
- Idiopathic Bullous Pemphigoid With Concurrent Gingival and Cutaneous Involvement: A Case Report.Cureus · 2025Article
- Clinical Outcomes and Prognostic Factors in Bullous Pemphigoid Patients: A 15-Year Review in China.American journal of clinical dermatology · 2025Article
- Bullous pemphigoid burden of disease, management and unmet therapeutic needs.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Eosinophils in Oral Disease: A Narrative Review.International journal of molecular sciences · 2024Review
- Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.Current oncology (Toronto, Ont.) · 2023Article
- Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy.Frontiers in immunology · 2023Review
- Associations between bullous pemphigoid and hematological diseases: Literature review on mechanistic connections and possible treatments.Frontiers in immunology · 2023Review
- Desquamative Gingivitis in the Context of Autoimmune Bullous Dermatoses and Lichen Planus-Challenges in the Diagnosis and Treatment.Diagnostics (Basel, Switzerland) · 2022Review
- Deciphering the Contribution of BP230 Autoantibodies in Bullous Pemphigoid.Antibodies (Basel, Switzerland) · 2022Review
- An Unusual TEN-Like Presentation of Juvenile Bullous Pemphigoid: A Diagnostic Challenge.Case reports in dermatological medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is the most common type of autoimmune bullous disease and is characterized by the presence of circulating anti-BP180 and/or anti-BP230 autoantibodies. Patients with BP often present with tense blisters and erythema, mainly on the trunk and limbs, but a few patients also have mucosal involvement. In this article, we discuss the fact that BP patients with mucosal involvement tend to have more serious conditions and their disease is more difficult to control. Potential risk factors for mucous involvement include earlier age at onset, drugs such as dipeptidyl peptidase-4 inhibitors, cancer, and blood/serum biomarkers, including lower eosinophil count, higher erythrocyte sedimentation rate, IgG autoantibodies against both the NH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.